Supplementary file 1_Herbal medicine for asymptomatic hyperuricemia: a systematic review and network meta-analysis.docx

BackgroundThere is still controversy in the medical community about whether asymptomatic hyperuricemia (AH) requires drug treatment. Herbal medicines (HM) are considered a potential intervention for the treatment of hyperuricemia.
ObjectivesThis study aimed to investigate the efficacy and safety of HM for asymptomatic HUA.
Materials and MethodsA Bayesian network meta-analysis was conducted for patients with asymptomatic HUA in randomized controlled trials identified in PubMed, Web of Science, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Wanfang database, China Biomedical Database (CBM), and China Science and Technology Journal Database (VIP) were searched from their inception to 1 Jan 2025. Outcomes included the serum uric acid (SUA), secondary outcomes (TC, TG, HDL or HDL-C, LDL or LDL-C, and traditional Chinese medicine symptom scores), and adverse events. This study was registered in PROSPERO (CRD42024459357).
ResultsAll evaluated HM formulations except Lily Plantago Seed tea demonstrated significant SUA reduction versus non drug therapy (NDT), achieving effect sizes spanning from -197.48 (95% CI −249.88 to −145.56) to −14.6 (95% CI −62.09 to 33.31). Probabilistic ranking identified Xuezhikang capsule as the most effective agent for SUA reduction (98.7%), with concurrent improvements in lipid profiles including TC, TG, and HDL levels. Therapeutic benefits extended to TCM symptom scores across all interventions (OR range 3.15–28.44), suggesting broader treatment potential for HUA management. No serious adverse events were documented throughout the trials.
ConclusionHM interventions demonstrate potential efficacy in managing AH, showing significant reductions in SUA levels alongside beneficial effects on lipid profile modulation and TCM symptom alleviation. While these findings suggest therapeutic promise, the preliminary nature of the evidence necessitates rigorous validation through methodologically robust clinical trials.
Systematic Review Registrationidentifier CRD42024459357.

背景
医学界目前对于无症状高尿酸血症（asymptomatic hyperuricemia, AH）是否需要接受药物治疗仍存在争议。草药制剂（Herbal medicines, HM）被认为是治疗高尿酸血症的潜在干预手段。

目的
本研究旨在探讨草药制剂用于无症状高尿酸血症的疗效与安全性。

材料与方法
本研究检索了建库至2025年1月1日期间，PubMed、Web of Science、考克兰图书馆（Cochrane Library）、Embase、中国知网（China National Knowledge Infrastructure, CNKI）、万方数据库、中国生物医学文献数据库（China Biomedical Database, CBM）及中国科技期刊数据库（VIP）中收录的无症状高尿酸血症患者相关随机对照试验，并开展贝叶斯网络荟萃分析。本研究的结局指标包括血尿酸（serum uric acid, SUA）、次要结局指标（总胆固醇TC、甘油三酯TG、高密度脂蛋白胆固醇HDL或HDL-C、低密度脂蛋白胆固醇LDL或LDL-C及中医症状积分）以及不良事件。本研究已在PROSPERO平台注册（注册号：CRD42024459357）。

结果
相较于非药物治疗（non drug therapy, NDT），除车前子百合茶外，所有受试草药制剂均可显著降低血尿酸水平，效应量范围为-197.48（95%置信区间：-249.88~-145.56）至-14.6（95%置信区间：-62.09~33.31）。概率排序结果显示，血脂康胶囊（Xuezhikang capsule）降低血尿酸的有效率最高（98.7%），同时可改善总胆固醇、甘油三酯及高密度脂蛋白胆固醇等血脂谱指标。所有干预措施均可改善中医症状积分（比值比OR范围为3.15~28.44），提示草药制剂在无症状高尿酸血症管理中具有更广泛的治疗潜力。本研究纳入的所有试验均未报告严重不良事件。

结论
草药制剂干预在无症状高尿酸血症管理中展现出潜在疗效，可显著降低血尿酸水平，同时对血脂谱调节及中医症状缓解具有积极作用。尽管本研究结果提示草药制剂具有治疗前景，但现有证据仍属初步阶段，需通过方法学严谨的临床试验开展进一步验证。

系统评价注册信息
注册号：CRD42024459357。